NASDAQ:APVO - Aptevo Therapeutics Stock Price, Price Target & More

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics (NASDAQ:APVO) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.07. The biotechnology company had revenue of $4.07 million for the quarter, compared to analyst estimates of $3.37 million. Aptevo Therapeutics had a negative return on equity of 47.64% and a net margin of 5.40%. View Aptevo Therapeutics' Earnings History.

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Aptevo Therapeutics.

2 Wall Street analysts have issued 12-month target prices for Aptevo Therapeutics' stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate Aptevo Therapeutics' share price to reach $10.50 in the next twelve months. View Analyst Ratings for Aptevo Therapeutics.

Some companies that are related to Aptevo Therapeutics include Mersana Therapeutics (MRSN), Isotechnika Pharma (AUPH), Clementia Pharmaceuticals (CMTA), Concert Pharmaceuticals (CNCE), Cytokinetics (CYTK), Obseva (OBSV), Evolus (EOLS), Zymeworks (ZYME), ProMetic Life Sciences (PFSCF), Dermira (DERM), Innate Pharma (IPHYF), Sinovac Biotech (SVA), Merus (MRUS), Clearside Biomedical (CLSD) and Depomed (DEPO).

News coverage about APVO stock has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a daily sentiment score of 0.19 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.52 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Aptevo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (5.44%), JPMorgan Chase & Co. (1.13%), Victory Capital Management Inc. (0.96%), Alambic Investment Management L.P. (0.88%), Park West Asset Management LLC (0.82%) and Spark Investment Management LLC (0.58%). Company insiders that own Aptevo Therapeutics stock include Marvin L White and Randy Joe Maddux. View Institutional Ownership Trends for Aptevo Therapeutics.

APVO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Aptevo Therapeutics.

APVO stock was acquired by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., JPMorgan Chase & Co., Park West Asset Management LLC, Dimensional Fund Advisors LP, Spark Investment Management LLC, Citadel Advisors LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Aptevo Therapeutics.

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $5.43.

Aptevo Therapeutics has a market capitalization of $125.35 million and generates $14.66 million in revenue each year. The biotechnology company earns $6.97 million in net income (profit) each year or ($1.53) on an earnings per share basis. Aptevo Therapeutics employs 121 workers across the globe.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]